Nine-month Angiographic and Two-year Clinical Follow-up of Novel Biodegradable-polymer Arsenic Trioxide-eluting Stent Versus Durable-polymer Sirolimus-eluting Stent For Coronary Artery Disease
Background: Despite great reduction of in-stent restenosis, first-generation drug-eluting stents (DESs) have increased the risk of late stent thrombosis due to delayed endothelialization. Arsenic trioxide, a natural substance that could inhibit cell proliferation and induce cell apoptosis, seems to...
Main Authors: | Li Shen, Wei Yang, Jia-Sheng Yin, Xue-Bo Liu, Yi-Zhe Wu, Ai-Jun Sun, Ju-Ying Qian, Jun-Bo Ge |
---|---|
Format: | Article |
Language: | English |
Published: |
Wolters Kluwer
2015-01-01
|
Series: | Chinese Medical Journal |
Subjects: | |
Online Access: | http://www.cmj.org/article.asp?issn=0366-6999;year=2015;volume=128;issue=6;spage=768;epage=773;aulast=Shen |
Similar Items
-
Tacrolimus combined with arsenic trioxide provides a three-in-one drug-eluting coronary stent integrating anti-restenosis, pro-endothelialization and anti-inflammation
by: Yaojia Zhang, et al.
Published: (2024-03-01) -
Clinical outcome of biodegradable polymer sirolimus-eluting stent and durable polymer everolimus-eluting stent in patients with diabetes
by: Ryota Kakizaki, et al.
Published: (2020-10-01) -
Ultrathin Strut Biodegradable Polymer Sirolimus‐Eluting Stent Versus Durable‐Polymer Everolimus‐Eluting Stent for Percutaneous Coronary Revascularization: 2‐Year Results of the BIOSCIENCE Trial
by: Rainer Zbinden, et al.
Published: (2016-03-01) -
The Twelve-Month Outcome of Biolimus Eluting Stent with Biodegradable Polymer Compared With an Everolimus Eluting Stent with Durable Polymer
by: Ahmad Separham, et al.
Published: (2011-11-01) -
Five‐Year Outcomes in Patients With Diabetes Mellitus Treated With Biodegradable Polymer Sirolimus‐Eluting Stents Versus Durable Polymer Everolimus‐Eluting Stents
by: Juan F. Iglesias, et al.
Published: (2019-11-01)